NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 184 filers reported holding NEKTAR THERAPEUTICS in Q2 2015. The put-call ratio across all filers is 0.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $594,000 | -56.5% | 35,818 | -39.3% | 0.04% | -60.0% |
Q2 2020 | $1,366,000 | +11.5% | 58,971 | -14.1% | 0.10% | +6.7% |
Q1 2020 | $1,225,000 | +103.2% | 68,651 | +145.7% | 0.09% | +147.2% |
Q4 2019 | $603,000 | -85.7% | 27,936 | -59.7% | 0.04% | -88.7% |
Q3 2018 | $4,227,000 | +15.6% | 69,340 | -7.4% | 0.32% | +25.7% |
Q2 2018 | $3,658,000 | +878.1% | 74,911 | +2028.8% | 0.25% | +873.1% |
Q1 2018 | $374,000 | -72.1% | 3,519 | -93.8% | 0.03% | -84.9% |
Q1 2017 | $1,340,000 | +100.3% | 57,092 | +4.7% | 0.17% | +62.3% |
Q4 2016 | $669,000 | +68.5% | 54,535 | +135.9% | 0.11% | +19.1% |
Q3 2016 | $397,000 | +12.8% | 23,120 | -6.6% | 0.09% | +93.5% |
Q2 2016 | $352,000 | +20.1% | 24,763 | +42.3% | 0.05% | +76.9% |
Q4 2015 | $293,000 | +29.6% | 17,400 | -15.7% | 0.03% | +36.8% |
Q3 2015 | $226,000 | -27.1% | 20,631 | -16.8% | 0.02% | -45.7% |
Q2 2015 | $310,000 | -67.4% | 24,800 | -71.3% | 0.04% | -63.9% |
Q1 2015 | $950,000 | +153.3% | 86,400 | +257.0% | 0.10% | +47.0% |
Q4 2014 | $375,000 | – | 24,200 | – | 0.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
TOBAM | 640,547 | $21,522,000 | 1.09% |
Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |